Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2016 Mar 1;30(6):1311–1319. doi: 10.1038/leu.2016.13

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2016 Macmillan Publishers Limited

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/

PMC Copyright notice

Effective targeted therapy by JAK, STAT and MEK inhibitors in primary EITL cells. (a) Stable cell lines were created by overexpressing GNAI2 wild-type and mutants in HuT78 and Jurkat cells. The expression of relevant proteins was assessed by western blot. (b) Representative images of pERK1/2 immunohistochemical staining in GNAI2 wild-type and mutant tumors. Magnification × 400. (c) Representative ex vivo cell viability assay in primary EITL cells treated with PD0325901 and Stattic for 72 h, and Tofacitinib, Trametinib and Gefitinib for 96 h. All results are normalized to the control (dimethyl sulfoxide (DMSO)) and presented as mean±s.d. The experiment was repeated at least two times with each inhibitor. (d) Immunoblots of indicated proteins in primary EITL cells treated with PD0325901, Tofacitinib and Trametinib for two and Stattic for 24 h at indicated concentrations.